European Parliament approves unitary patent rules

12 December 2012

Following the historic vote yesterday in the European Union Parliament to approve the unitary patent regulation, which is intended to lead to one patent and one patent court system for EU member states, EU inventors will soon be able to get a unitary patent at last.

Over 30 years of talks, a new regime will cut the cost of an EU patent by up to 80%, making it more competitive vis-a-vis the USA and Japan. Members   of the European Parliament (MEPs) cut costs for small firms and tailored the regime to their needs, in a compromise deal with the Council endorsed by Parliament on Tuesday,

In three separate voting sessions, MEPs approved the so-called "EU patent package" (unitary patent, language regime and unified patent court). The Rapkay report was approved by 484 votes to 164 with 35 abstentions. The Baldassarre resolution was approved by 481 votes to 152 with 49 abstentions. The Lehne report was approved by 483 votes to 161, with 38 abstentions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology